• Alzheimer's disease;
  • β-amyloid;
  • non-steroidal anti-inflammatory drugs (NSAIDs);
  • nuclear factor-κB (NF-κB);
  • R-flurbiprofen;
  • R-ibuprofen


Non-steroidal anti-inflammatory drugs (NSAIDs) have been associated with reduced risk for Alzheimer's disease (AD) and selected NSAIDs racemates suppress β-amyloid (Aβ) accumulation in vivo and Aβ42 production in vitro. Clinical use of NSAIDs for preventing or treating AD has been hampered by dose-limiting toxicity believed to be due to cyclooxygenase (COX)-inhibition that is reportedly not essential for selective Aβ42 reduction. Profens have racemates and R-enantiomers were supposed to be inactive forms. Here we demonstrate that R-ibuprofen and R-flurbiprofen, with poor COX-inhibiting activity, reduce Aβ42 production by human cells. Although these R-enantiomers inhibit nuclear factor-κB (NF-κB) activation and NF-κB can selectively regulate Aβ42, Aβ42 reduction is not mediated by inhibition of NF-κB activation. Because of its efficacy at lowering Aβ42 production and low toxicity profile, R-flurbiprofen is a strong candidate for clinical development.